RGNCY-0130 (JMV5884 CDK5 inhibitor)

SOLD OUT!!  E-mail us at info@reagency.co if you are interested in this product.

JMV5884 is the most potent of a series of compounds to uniquely inhibit CDK5 by targeting a site other than the ATP pocket.  JMV5884 was shown to inhibit the proliferation of U87 glioblastoma cells in vitro.  By targeting CDK5 at a novel site outside the ATP binding site, JMV5884 presents an attractive lead for the treatment of glioblastoma as it potentially bypasses the limitations of existing ATP-competitive inhibitors targeting CDK5/p25 interface.  Therefore, JMV5884 is a promising lead for glioblastoma treatment and provides a new therapeutic perspective for neurodegenerative disease.

Systematic Name:  2-(((6-amino-1H-benzo[d]imidazol-2-yl)thio)methyl)-3-(3-chlorophenyl)quinazolin-4(3H)-one

SMILES:  O=C1N(C2=CC(Cl)=CC=C2)C(CSC3=NC(C=CC(N)=C4)=C4N3)=NC5=CC=CC=C51

Formula:  C22H16ClN5OS 

Mol Wt: 433.91